Fumihiro Oshita
Kanagawa Prefectural Hospital
117 Papers
1.1K Citations
Fumihiro Oshita is an academic researcher from Kanagawa Prefectural Hospital. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 26, co-authored 117 publications.
Chat about Author
Papers
Clinicopathological Study of the Development of Adenocarcinoma of the Lung
Atsushi Fujita,Yoichi Kameda,Haruhiko Nakayama,Katsuya Watanabe,Kazumasa Noda,Kozo Yamada,Fumihiro Oshita,Haruhiro Saito,Aki Mitsuda,Tomoyuki Goya +9 more
TL;DR: Analysis of bronchioloalveolar carcinoma and alveolar septal fibrosis types concludes that conventional BAC is superior to DA type in terms of overall efficiency.
1
Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
TL;DR: This phase II study evaluated the feasibility and safety of a CDDP/PEM/BEV regimen in the treatment of NS-NSCLC with EGFR wild type in Japanese patients to determine the response rate, PFS, OS and rates of adverse events.
1
[CT-image analysis of resected peripheral adenocarcinomas of the lung less than 1 cm in diameter].
Takeshi Isobe,Kouzo Yamada,Fumihiro Oshita,Ikuo Nomura,Kazumasa Noda,Youichi Kameda,Michio Yamakido,Masahiro Kaneko +7 more
TL;DR: High-resolution CT images revealed air spaces within pulmonary nodules in 82% of tumors, an ill-defined margin in 91%, and involvement of vessels in 91%.
Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Car cinoma of the Lung
Seiji Niho,Hirotsugu Kenmotsu,Ikuo Sekine,Genichiro Ishii,Yuichi Ishikawa,Masayuki Noguchi,Fumihiro Oshita,Shun-ichi Watanabe,Ryu Nakajima,Hirohito Tada,Kanji Nagai +10 more
- 01 Jan 2013
TL;DR: Combination chemotherapy with irinotecan and cisplatin was active in patients with advanced large-cell neuroendocrine carcinoma (LCNEC) of the lung, but the RR and the overall survival period seemed to be inferior to those among the patients with SCLC.
Patent
Use of diagnostic marker for malignancy of early-stage pulmonary adenocarcinoma focused on epithelial mesenchymal transition
Akiko Okayama,Horiuchi Yayoi,Yana Akihide,Hisashi Hirano,Yohei Miyagi,Haruhiko Nakayama,Hiroyuki Ito,Fumihiro Oshita,Tomoyuki Yokose,Kozo Yamada +9 more
- 15 Dec 2016
TL;DR: In this paper, a method for inspecting malignancy of early-stage pulmonary adenocarcinoma regarding a sample derived from a subject includes detecting phosphorylation of at least one portion selected from a group consisting of 516-th tyrosine of TrkC, 1404-th TNS1, and 92-nd serine of SSFA2.